Page 13 - 2 Director Reports (Annexure) 2021.cdr

58-59

• Scale up of Amorphous Dapagliflozin in New Formulations Developed and • Teneligliptin 20 mg Filmcoated tablets • Methyl cobalamin 1500 mcg+Alpha Lipoic
Anti-diabetic category was completed. commercialized in different therapeutic developed & commercialized under Acid 100 mg +
Validation of Amorphous Dapagliflozin is categories antidiabetic category.
• Vitamin D3 1000IU+Pyridoxine HCl 3 mg +
planned for its USDMF filing.
• Hand Sanitizers (IPA 70% gel based), Hand • Linezolid 100 mg/5 ml developed & Folic Acid 1.5 mg tabs under dietary
• Under anti-diabetic category, the Sanitizer (Chlorhexidine gluconate,2.5%, commercialized under antibacterial supplements.
commercialization of Linagliptin Form C was Ethanol 70%), Hand Sanitizer (Ethyl alcohol category. • Milk of Magnesia 3.75 ml+Liquid Paraffin
done. Its USDMF/ CNDMF filing are also 70% gel based), Hand Sanitizer
• Teneligliptin 20 & Metformin 500 mg tablets 1.25 ml Sodium Picosulfate suspension
being planned. (Chlorhexidine gluconate 0.3%, Cetrimide
under antidiabetic category. Atorvastatin under antacid category.
0.6%) Solution under Sanitizers &
• Cost-effective enzymatic process using tablets 5 mg under antidiabetic category. • Bilastine 20 mg Tab under antihistaminic/
Disinfectant category during COVID
green chemistry are being further explored Development under progress: antiallergic category.
for Rosuvastatin/Atorvastatin & Sitagliptin. pandemic.
• Tofacitinib 5 mg Tablets -antirheumatic • Montelukast 10 mg + Bilastine 20 mg Tab
• Gabapentene 100 mg (FC) Tablets under
• Commercialization of Rivaroxaban in Anti-
neuronic disorder segment. & immunosuppressant category. under antihistaminic/antiallergic category.
Coagulant category was done followed by
its process validation. Its USDMF & CEP filing • HCQ (Hydroxychloroquine 200 mg (FC) • Oseltamivir capsules 75 mg under antiviral • Telmisartan 80 mg +Amlodipine 5 mg
are planned for the current year. tablets underdeveloped & amp; segment. bilayered tablets-under hypertensive
Commercialized Antimalarial & COVID • Silodosin capsules 8 mg under prostatic segment.
• Commercialization of Apixaban in Anti-
19 treatment. hypertrophy agent. • Saroglitazar 2/4 mg tablets a novel
Coagulant category was done followed by
its process validation. Its USDMF has been • Doxofylline 400 mg (UC) tablets developed • Ranolazine ER tablets 500/1000 mg under antidiabetic formulation under antidiabetic
filed. Further USDMF is planned to be filed & a m p ; c o m m e r c i a l i z e d u n d e r cardiac segment. category.
for its another polymorph, Apixaban Form Antiasthamatic category. • Saxagliptin 2.5/5 mg tablet under
• Mycophenolate mofetil 500 mg tablets
H3 and Amorphous Form during current antidiabetic category. Saxagliptin 2.5/5 +
• Calciquick K27 (FC) Tablets developed & under immunosuppressant category. Myco-
year. Metformin 500/1000 mg tablets under
commercialized under dietary supplement phenolate sodium 180/360 mg tablets
• Development & Transfer of Technology of category. under immunosuppressant category. antidiabetic category.
Ertugliflozin L-Pyroglutamate in Anti- • Cilnidipine film coated tablets 10 mg Sirolimus 1/2mg tablets under immunosup- • Dapagliflozin 5/10 mg+ Metformin
diabetic category to plant. Its scale up and pressant category. 500/1000 mg Film coated tablets
developed & commercialized under
process validation is planned for current antidiabetic category.
antihypertensive category. • Torsemide 5/10/20 mg tablet under Diuretic
year.
• Levetiracetam tablets 500 & 750 mg film category. • Azithromycin dry syrup 200 mg/5 ml under
• Development of Technology for coated, developed & commercialized • Fimasartan 30/60/120 mg tablets under antibiotic category.
Hydroxychloroquine in Anti-Malarial
under antipsychotic category. antihypertensive category. • Aspirin 75 (Tabs) + Atorvastatin 10 mg
category, Hydrochlorothiazide in Diuretics (blend) in capsules under cardiac segment.
category and Amlodipine besylate in Anti- • Cough-X DX Syrup (Phenylephrine 5+ • Brivaracetam 50/75/100 mg tab under Montelukast 10 mg+ Doxophylline 400 mg
Hypertensive category, were completed. Dextromethorphan 15+ Chlorpheniramine antiepileptic category.
2 mg (Syrup) developed and commercialized ER tablets under Anti-asthmatic category.
• Development & Transfer of Technology of under cold & cough category. • Prucalopride 1/2mg Tab under chronic 2) Benefits derived as a result of Research
cost-effective route of Canagliflozin idiopathic constipation. Oxcarbazepine and Development (R&D) activities:
Hemihydrate and Alogliptin of Anti-diabetic • D- Quatro Drop 60000 IU developed & 150/300/450/600 mg Tab under
category to plant. commercialized under vitamin supplement. anticonvulsant category. Over the years, the company is working
• Commercialization of Edoxaban Tosylate • Dapagliflozin 5 & 10 mg Film coated tablets • Dabigatran Mesylate capsules 75/110/150 continuously to improve its processes to deliver
better quality products at affordable price for its
Monohydrate in Anti-Coagulant category developed & commercialized under mg under cardiac segment. Montelukast+ business segments comprising of API business,
completed. Further USDMF is also planned. antidiabetic category. Desloratadine Syrup (First time in INDIA,
Patent has filed in India). finished dosages business and OTC business.
• Development & Transfer of Technology of • Rivaroxaban 10 & 20 mg developed & The benefits derived because of the above
Febuxostat in Anti-Gout category to plant. commercialized under cardiac segments. • Gabapentin 400 +Nortriptyline 10 mg Tab efforts including new product development,
Its validation is planned for the current year. • Ursodeoxycholic Acid 600 mg film coated under anticonvulsant category.
product improvement, cost reduction, greener
• Development of Improved Chemical tablets developed & commercialized under • Trypsin48+Bromelaine90 + Rutoside technologies and import substitution etc. are
Entities/ Novel chemical Entities (NCE) is Liver dysfunction category. Trihydrate 100 + diclofenac Sodium 50 mg detailed hereunder:
under progress in collaboration with NIPER • Nebivolol 5 mg tablets developed & Tab Under anti-inflammatory & pain • Indian patent application entitled "Process
Mohali. The Molecular docking studies for commercialized under Antihypertensive management. for purification of Fexofenadine
several lead molecules is in progress. category. • Aspirin 75+Clopidogrel 150 mg Bilayered Intermediates" was granted by Indian Patent
tablets- Under Cardiac segment. office as IN351665.
• Oxcarbazepine 300 mg Oral Suspension • PCT National phase application of
under anticonvulsant category. Rosuvastatin Calcium of new polymorph